{"id":75580,"date":"2026-08-20T12:23:46","date_gmt":"2026-08-20T04:23:46","guid":{"rendered":"https:\/\/flcube.com\/?p=75580"},"modified":"2026-08-20T12:23:47","modified_gmt":"2026-08-20T04:23:47","slug":"carsgen-1h-2026-satricabtagene-autoleucel-wins-nmpa-approval-as-worlds-first-car-t-for-solid-tumors-cash-runway-seen-into-2030","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75580","title":{"rendered":"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World&#8217;s First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CARsgen Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2171:HKG\">HKG: 2171<\/a>) reported interim results for the first half of 2026, highlighted by a landmark regulatory milestone: <strong>Satricabtagene Autoleucel received NMPA approval for market launch in June 2026<\/strong>, becoming the <strong>world&#8217;s first and only CAR\u2011T product approved for the treatment of solid tumors<\/strong>. The company recorded <strong>revenue of approximately RMB 62 million<\/strong>, primarily from <strong>Zevorcabtagene Autoleucel<\/strong>, and expects sufficient cash to fund operations into 2030.<\/p>\n\n\n\n<h2 id=\"h-1h-2026-financial-amp-operating-highlights\" class=\"wp-block-heading\">1H 2026 Financial &amp; Operating Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>1H 2026<\/th><\/tr><\/thead><tbody><tr><td><strong>Revenue<\/strong><\/td><td>~RMB 62 million (primarily Zevorcabtagene Autoleucel)<\/td><\/tr><tr><td><strong>Zevorcabtagene Autoleucel Orders<\/strong><\/td><td>110 valid orders from commercial partner Huadong Medicine<\/td><\/tr><tr><td><strong>Cash &amp; Cash Equivalents (30 Jun 2026)<\/strong><\/td><td>~RMB 1.4 billion<\/td><\/tr><tr><td><strong>Expected Cash (end\u20112026)<\/strong><\/td><td>No less than RMB 1.2 billion<\/td><\/tr><tr><td><strong>Cash Runway<\/strong><\/td><td>Sufficient to fund operations into 2030<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-commercial-amp-clinical-milestones\" class=\"wp-block-heading\">Commercial &amp; Clinical Milestones<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Zevorcabtagene Autoleucel:<\/strong> 110 valid orders received from commercial partner <strong>Huadong Medicine<\/strong> during the first half, driving the company&#8217;s revenue generation.<\/li>\n\n\n\n<li><strong>Satricabtagene Autoleucel:<\/strong> <strong>NMPA approval in June 2026<\/strong> makes it the <strong>world&#8217;s first and only CAR\u2011T therapy approved for solid tumors<\/strong> \u2014 a global first for the cell\u2011therapy field.<\/li>\n\n\n\n<li><strong>ASCO 2026 Data:<\/strong> Long\u2011term follow\u2011up results from the <strong>first\u2011line sequential therapy of Satricabtagene Autoleucel for gastric cancer<\/strong> were presented at the <strong>2026 ASCO Annual Meeting<\/strong>, reinforcing the product&#8217;s clinical profile in earlier treatment settings.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-liquidity-amp-cash-runway\" class=\"wp-block-heading\">Liquidity &amp; Cash Runway<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cash and cash equivalents stood at approximately RMB 1.4 billion<\/strong> as of 30 June 2026.<\/li>\n\n\n\n<li>Management expects cash and cash equivalents to remain <strong>no less than RMB 1.2 billion by end\u20112026<\/strong>.<\/li>\n\n\n\n<li>Taking into account operational factors, CARsgen expects <strong>sufficient cash to fund operations into 2030<\/strong>, providing substantial runway for commercialization and pipeline development.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Category\u2011Defining Approval:<\/strong> Satricabtagene Autoleucel&#8217;s status as the first approved CAR\u2011T for solid tumors breaks a long\u2011standing barrier in cell therapy, opening a commercial beachhead in a field previously confined to hematologic malignancies.<\/li>\n\n\n\n<li><strong>Commercial Traction:<\/strong> 110 first\u2011half orders for Zevorcabtagene Autoleucel through Huadong Medicine signal building market adoption of CARsgen&#8217;s marketed portfolio.<\/li>\n\n\n\n<li><strong>Front\u2011Line Expansion Potential:<\/strong> Long\u2011term ASCO follow\u2011up data in first\u2011line gastric cancer supports future label and setting expansion for Satricabtagene Autoleucel.<\/li>\n\n\n\n<li><strong>Balance\u2011Sheet Resilience:<\/strong> A stated cash runway into 2030 reduces financing risk during the critical early commercialization years.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding CARsgen&#8217;s cash position, commercial adoption, and product development. Actual results may differ due to risks including market uptake, pricing and reimbursement dynamics, clinical outcomes, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081801887.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026081801887.\"><\/object><a id=\"wp-block-file--media-13ebc033-9cd5-4709-ba19-176020e25b68\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081801887.pdf\">2026081801887<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081801887.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-13ebc033-9cd5-4709-ba19-176020e25b68\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARsgen Therapeutics (HKG: 2171) reported interim results for the first half of 2026, highlighted by&#8230;<\/p>\n","protected":false},"author":1,"featured_media":75582,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[379,27,1188],"class_list":["post-75580","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-carsgen-therapeutics","tag-finanical-reports","tag-hkg-2171"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World&#039;s First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CARsgen Therapeutics (HKG: 2171) reported interim results for the first half of 2026, highlighted by a landmark regulatory milestone: Satricabtagene Autoleucel received NMPA approval for market launch in June 2026, becoming the world&#039;s first and only CAR\u2011T product approved for the treatment of solid tumors. The company recorded revenue of approximately RMB 62 million, primarily from Zevorcabtagene Autoleucel, and expects sufficient cash to fund operations into 2030.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75580\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World&#039;s First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030\" \/>\n<meta property=\"og:description\" content=\"CARsgen Therapeutics (HKG: 2171) reported interim results for the first half of 2026, highlighted by a landmark regulatory milestone: Satricabtagene Autoleucel received NMPA approval for market launch in June 2026, becoming the world&#039;s first and only CAR\u2011T product approved for the treatment of solid tumors. The company recorded revenue of approximately RMB 62 million, primarily from Zevorcabtagene Autoleucel, and expects sufficient cash to fund operations into 2030.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75580\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-20T04:23:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-20T04:23:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2003.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75580#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75580\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World&#8217;s First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030\",\"datePublished\":\"2026-08-20T04:23:46+00:00\",\"dateModified\":\"2026-08-20T04:23:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75580\"},\"wordCount\":414,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75580#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2003.webp\",\"keywords\":[\"CARsgen Therapeutics\",\"Finanical Reports\",\"HKG: 2171\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75580#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75580\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75580\",\"name\":\"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World's First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75580#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75580#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2003.webp\",\"datePublished\":\"2026-08-20T04:23:46+00:00\",\"dateModified\":\"2026-08-20T04:23:47+00:00\",\"description\":\"CARsgen Therapeutics (HKG: 2171) reported interim results for the first half of 2026, highlighted by a landmark regulatory milestone: Satricabtagene Autoleucel received NMPA approval for market launch in June 2026, becoming the world's first and only CAR\u2011T product approved for the treatment of solid tumors. The company recorded revenue of approximately RMB 62 million, primarily from Zevorcabtagene Autoleucel, and expects sufficient cash to fund operations into 2030.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75580#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75580\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75580#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2003.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2003.webp\",\"width\":1080,\"height\":608,\"caption\":\"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World's First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75580#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World&#8217;s First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World's First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030 - Insight, China&#039;s Pharmaceutical Industry","description":"CARsgen Therapeutics (HKG: 2171) reported interim results for the first half of 2026, highlighted by a landmark regulatory milestone: Satricabtagene Autoleucel received NMPA approval for market launch in June 2026, becoming the world's first and only CAR\u2011T product approved for the treatment of solid tumors. The company recorded revenue of approximately RMB 62 million, primarily from Zevorcabtagene Autoleucel, and expects sufficient cash to fund operations into 2030.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75580","og_locale":"en_US","og_type":"article","og_title":"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World's First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030","og_description":"CARsgen Therapeutics (HKG: 2171) reported interim results for the first half of 2026, highlighted by a landmark regulatory milestone: Satricabtagene Autoleucel received NMPA approval for market launch in June 2026, becoming the world's first and only CAR\u2011T product approved for the treatment of solid tumors. The company recorded revenue of approximately RMB 62 million, primarily from Zevorcabtagene Autoleucel, and expects sufficient cash to fund operations into 2030.","og_url":"https:\/\/flcube.com\/?p=75580","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-20T04:23:46+00:00","article_modified_time":"2026-08-20T04:23:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2003.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75580#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75580"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World&#8217;s First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030","datePublished":"2026-08-20T04:23:46+00:00","dateModified":"2026-08-20T04:23:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75580"},"wordCount":414,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=75580#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2003.webp","keywords":["CARsgen Therapeutics","Finanical Reports","HKG: 2171"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75580#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75580","url":"https:\/\/flcube.com\/?p=75580","name":"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World's First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=75580#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=75580#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2003.webp","datePublished":"2026-08-20T04:23:46+00:00","dateModified":"2026-08-20T04:23:47+00:00","description":"CARsgen Therapeutics (HKG: 2171) reported interim results for the first half of 2026, highlighted by a landmark regulatory milestone: Satricabtagene Autoleucel received NMPA approval for market launch in June 2026, becoming the world's first and only CAR\u2011T product approved for the treatment of solid tumors. The company recorded revenue of approximately RMB 62 million, primarily from Zevorcabtagene Autoleucel, and expects sufficient cash to fund operations into 2030.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75580#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75580"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=75580#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2003.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2003.webp","width":1080,"height":608,"caption":"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World's First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75580#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World&#8217;s First CAR\u2011T for Solid Tumors; Cash Runway Seen Into 2030"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2003.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75580"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75580\/revisions"}],"predecessor-version":[{"id":75583,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75580\/revisions\/75583"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/75582"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}